Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.

Berenstein R, Blau IW, Kar A, Cay R, Sindram A, Seide C, Blau O.

J Exp Clin Cancer Res. 2014 May 21;33:44. doi: 10.1186/1756-9966-33-44.

2.

Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.

Gorniak P, Ejduk A, Borg K, Makuch-Lasica H, Nowak G, Lech-Maranda E, Prochorec-Sobieszek M, Warzocha K, Juszczynski P.

Eur J Haematol. 2016 Feb;96(2):181-7. doi: 10.1111/ejh.12566. Epub 2015 May 13.

PMID:
25891904
3.

Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.

Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ, Luthra R.

J Mol Diagn. 2011 Nov;13(6):678-86. doi: 10.1016/j.jmoldx.2011.06.004. Epub 2011 Sep 1.

4.

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.

Berenstein R, Blau IW, Suckert N, Baldus C, Pezzutto A, Dörken B, Blau O.

J Exp Clin Cancer Res. 2015 May 22;34:55. doi: 10.1186/s13046-015-0173-2.

5.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

6.

[Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].

Shang Z, Wang D, Xiao M, Wang J, Li TJ, Zhao YC, Li CR, Zhou JF.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):607-12. doi: 10.7534/j.issn.1009-2137.2013.03.014. Chinese.

PMID:
23815907
7.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

8.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman O, Contentin N, Bordessoule D, Pautas C, Botton Sd, Revel Td, Terre C, Fenaux P, Thomas X, Castaigne S, Dombret H, Preudhomme C.

Leukemia. 2012 Jun;26(6):1247-54. doi: 10.1038/leu.2011.382. Epub 2012 Jan 13.

PMID:
22289988
9.

Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.

Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2011 Aug;57(2):204-9. doi: 10.1002/pbc.23179. Epub 2011 Apr 18.

10.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C.

Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645.

11.

Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia.

Ashraf S, Noguera NI, Di Giandomenico J, Zaza S, Hasan SK, Lo-Coco F.

Ann Hematol. 2013 Oct;92(10):1319-23. doi: 10.1007/s00277-013-1868-0. Epub 2013 Aug 15.

PMID:
23949315
12.

Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.

Liang DC, Liu HC, Yang CP, Jaing TH, Hung IJ, Yeh TC, Chen SH, Hou JY, Huang YJ, Shih YS, Huang YH, Lin TH, Shih LY.

Blood. 2013 Apr 11;121(15):2988-95. doi: 10.1182/blood-2012-06-436782. Epub 2013 Jan 30.

13.

Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.

Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R.

Am J Clin Pathol. 2011 Jan;135(1):35-45. doi: 10.1309/AJCPD7NR2RMNQDVF.

14.

Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.

Elsayed GM, Nassar HR, Zaher A, Elnoshokaty EH, Moneer MM.

J Egypt Natl Canc Inst. 2014 Mar;26(1):43-9. doi: 10.1016/j.jnci.2013.11.001. Epub 2013 Nov 27.

15.

Clinical implications of novel mutations in epigenetic modifiers in AML.

Abdel-Wahab O, Patel J, Levine RL.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33. doi: 10.1016/j.hoc.2011.09.013. Epub 2011 Oct 29. Review.

PMID:
22093580
16.

Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.

Aref S, Kamel Areida el S, Abdel Aaal MF, Adam OM, El-Ghonemy MS, El-Baiomy MA, Zeid TA.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):550-5. doi: 10.1016/j.clml.2015.05.009. Epub 2015 Jun 6.

PMID:
26189213
17.

[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Jia ZX, Zhou M, Chao HY, Lu XZ, Zhang R, Cen L, Xiao R, Jiang NK.

Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Chinese.

PMID:
22781800
18.

High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.

Kao HW, Liang DC, Kuo MC, Wu JH, Dunn P, Wang PN, Lin TL, Shih YS, Liang ST, Lin TH, Lai CY, Lin CH, Shih LY.

Oncotarget. 2015 Oct 20;6(32):33217-25. doi: 10.18632/oncotarget.5202.

19.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M.

Leukemia. 2014 Sep;28(9):1774-83. doi: 10.1038/leu.2014.124. Epub 2014 Apr 4. Review. Erratum in: Leukemia. 2015 Feb;29(2):516.

20.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

Nomdedéu J, Hoyos M, Carricondo M, Esteve J, Bussaglia E, Estivill C, Ribera JM, Duarte R, Salamero O, Gallardo D, Pedro C, Aventin A, Brunet S, Sierra J.

Leuk Res. 2012 Aug;36(8):990-7. doi: 10.1016/j.leukres.2012.03.019. Epub 2012 Apr 19.

PMID:
22520341

Supplemental Content

Support Center